Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
NCT #
NCT04589845
Condition(s)
Solid Tumor
Molecular Target(s)
AKT1/2/3 mutant, ALK fusion, HER2, MDM2, NTR, NTRK1/2/3 fusion, PIK3CA, ROS1, TMB-high, TP53 wild-type
Drug Classification(s)
Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy
Agents(s)
Receipt of XL102 or any other selective CDK7 inhibitor
Phase(s)
II
Mechanism of Action
- GDC-0077 – PI3K inhibitor
- Idasanutlin – MDM2 protein antagonist
- Alectinib – ALK kinase inhibitor
- Trastuzumab Emtansine – HER2 antibody-drug conjugate
- Ipatasertib – AKT inhibitor
- Atezolizumab – PD-L1 immunotherapy
- Entrectinib – Inhibitor of the tyrosine kinases TrkA, TrkB, TrkC, ROS1, and ALK
Purpose
- The purpose of this study is to compare the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body’s immune system fight cancer cells) on participants who have solid tumors with specific genetic alterations or with a high number of mutations.
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.